ABSTRACT
Pharmacogenomics (PGx) can provide optimized treatment to individual patients while potentially reducing healthcare costs. However, widespread implementation remains absent. We performed a pilot study of PGx screening in Dutch outpatient hospital care to identify the barriers and facilitators to implementation experienced by patients (n=165), pharmacists (n=58) and physicians (n=21). Our results indeed suggest that the current practical experience of healthcare practitioners (HCPs) with PGx is limited, that proper education is necessary, that patients want to know the exact implications of the results, and that there is an unclear allocation of responsibilities between HCPs about who should discuss PGx with patients and apply PGx results in healthcare. We observed a positive attitude toward PGx among all the stakeholders in our study, and among patients this was independent of the occurrence of drug- gene interactions during their treatment. Facilitators included the availability of and adherence to Dutch Pharmacogenetic Working Group guidelines. While Clinical Decision Support (CDS) is available and valued in our medical center, the lack of availability of CDS might be an important barrier within Dutch healthcare in general.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by a University Medical Center Groningen (UMCG) Healthy Ageing Pilot fund (CDO15.0022) and by a Netherlands Organization for Scientific Research Spinoza Prize (SPI 92-266 to C.W.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Medical Ethics Review Board of the UMCG (reference: 2017.266).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available upon reasonable request.